Gyula Mózsik
Research Subjects
Research Interests
Gyula Mózsik has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
L Nagy
23 shared publicationsT Jávor
21 shared publications- Áron Vincze
Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary
20 shared publications F Tárnok
14 shared publicationsI Patty
13 shared publicationsG Sütö
11 shared publications
Latest Publications
- 4 May 2005
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 43 (05) , 58
The change of motility compared with the gastric-acid secretion after atropine administration in rats
The vagal nerve has important role in the regulation of gastric acid secretion and motility. It was not known how the parts of gastric function are influenced by the effects of cholinergic innervation. Early study proved that the ED50 value in inhibition of gastric acid secretion of atropine is 1.78µmol/kg (-log: 5.75)(Mózsik and Jávor. Dig. Dis. Sci. 1988;33:92–105). The aims of study were to determinate the ED50 value of atropine in relation the decrease of gastric emptying and to compare the both ED50 levels. Materials and methods: The observation was carried out on Sprague-Dawley rats weighing 210–230g of body weight. The animals were fasted for 24h before the experiments but water was given freely. The test solution contained 1.5% of methylcellulose dispergated in water painted with 0.05% phenol-red. The rats were given 1.5ml of test solution intragastrically. Atropine was given i.p. in 0.001 (1.48 nmol)-0.005–0.01–0.05–0.1–0.5–1.0 (1.48µmol) mg/kg doses at 30min before the test solution administration. The rats were killed at 20min after methylcellulose application, when the phenol-red content was measured spectrophotometrically in the stomach. The stomach emptying was calculated in percent values. Result: After the determination of dose-dependent decrease of gastric emptying the ED50 value derived 0.108µmol/kg (-log: 6.97). Conclusion: The effect of atropine is ten times higher on the gastric motility than on the acid secretion in rats. The study was supported by grants of National Research Found (OTKA), Hungary (No. F037639, No. F042912).
- 4 May 2005
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 43 (05) , 58
The change of motility compared with the gastric-acid secretion after atropine administration in rats
The vagal nerve has important role in the regulation of gastric acid secretion and motility. It was not known how the parts of gastric function are influenced by the effects of cholinergic innervation. Early study proved that the ED50 value in inhibition of gastric acid secretion of atropine is 1.78µmol/kg (-log: 5.75)(Mózsik and Jávor. Dig. Dis. Sci. 1988;33:92–105). The aims of study were to determinate the ED50 value of atropine in relation the decrease of gastric emptying and to compare the both ED50 levels. Materials and methods: The observation was carried out on Sprague-Dawley rats weighing 210–230g of body weight. The animals were fasted for 24h before the experiments but water was given freely. The test solution contained 1.5% of methylcellulose dispergated in water painted with 0.05% phenol-red. The rats were given 1.5ml of test solution intragastrically. Atropine was given i.p. in 0.001 (1.48 nmol)-0.005–0.01–0.05–0.1–0.5–1.0 (1.48µmol) mg/kg doses at 30min before the test solution administration. The rats were killed at 20min after methylcellulose application, when the phenol-red content was measured spectrophotometrically in the stomach. The stomach emptying was calculated in percent values. Result: After the determination of dose-dependent decrease of gastric emptying the ED50 value derived 0.108µmol/kg (-log: 6.97). Conclusion: The effect of atropine is ten times higher on the gastric motility than on the acid secretion in rats. The study was supported by grants of National Research Found (OTKA), Hungary (No. F037639, No. F042912).
- 3 March 2002
- Vol. 143 (9) , 447-50
[Prevalence of Leiden mutation in various gastrointestinal disorders].
Molecular biological examinations have been carried out by the authors from 1995 in patients with different haemostasis, very recently these types of the studies were done in patients with different gastrointestinal (Helicobacter pylori-induced gastritis, hepatitis C infection, ileitis terminalis, ulcerative colitis, colon polyposis and adenocarcinoma in polyps) disorders. The Leiden mutation was detected by polymerase chain reaction (PCR) in 1354 healthy persons and patients with different GI disorders. The results of Leiden prevalence in patients with different gastrointestinal disorders were compared to those obtained in patients with venous thrombosis and familiar thrombophilia. The authors indicated that the prevalence of heterozygous Leiden positive persons was 5.9% in healthy (n = 87) and blood donors (n = 600). The prevalence of heterozygous Leiden mutation was 27% in patents who under went venous thrombosis (n = 300; P < 0.001), 38% in patients with familial thrombophilia (n = 116; P < 0.001). The prevalence of Leiden mutation was 0 in patients with Helicobacter pylori-induced gastritis (n = 24), 8% in hepatitis C infections (n = 75), 14.28% in Crohn's disease, (n = 49; P < 0.01), 27.5% in ulcerative colitis (n = 35; P < 0.001), 44% in colon polyposis (n = 59; P < 0.001) and 55% in situ adenocarcinomas (in polyposis) (n = 9; P < 0.001). The presented results suggest that the Leiden mutation is involved in patients with different inflammatory bowel disease, colon polyposis, as one of the suggested genetic factors.
- 3 March 2002
- Vol. 143 (9) , 447-50
[Prevalence of Leiden mutation in various gastrointestinal disorders].
Molecular biological examinations have been carried out by the authors from 1995 in patients with different haemostasis, very recently these types of the studies were done in patients with different gastrointestinal (Helicobacter pylori-induced gastritis, hepatitis C infection, ileitis terminalis, ulcerative colitis, colon polyposis and adenocarcinoma in polyps) disorders. The Leiden mutation was detected by polymerase chain reaction (PCR) in 1354 healthy persons and patients with different GI disorders. The results of Leiden prevalence in patients with different gastrointestinal disorders were compared to those obtained in patients with venous thrombosis and familiar thrombophilia. The authors indicated that the prevalence of heterozygous Leiden positive persons was 5.9% in healthy (n = 87) and blood donors (n = 600). The prevalence of heterozygous Leiden mutation was 27% in patents who under went venous thrombosis (n = 300; P < 0.001), 38% in patients with familial thrombophilia (n = 116; P < 0.001). The prevalence of Leiden mutation was 0 in patients with Helicobacter pylori-induced gastritis (n = 24), 8% in hepatitis C infections (n = 75), 14.28% in Crohn's disease, (n = 49; P < 0.01), 27.5% in ulcerative colitis (n = 35; P < 0.001), 44% in colon polyposis (n = 59; P < 0.001) and 55% in situ adenocarcinomas (in polyposis) (n = 9; P < 0.001). The presented results suggest that the Leiden mutation is involved in patients with different inflammatory bowel disease, colon polyposis, as one of the suggested genetic factors.
- 31 December 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 483-487
Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity
- 31 December 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 483-487
Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity
- 31 December 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 229-237
The key-role of vagal nerve and adrenals in the cytoprotection and general gastric mucosal integrity
- 31 December 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 229-237
The key-role of vagal nerve and adrenals in the cytoprotection and general gastric mucosal integrity
- 8 November 2001
- Published by Elsevier in Life Sciences
- Vol. 69 (25-26) , 3103-3112
Mechanisms of action of retinoids in gastrointestinal mucosal protection in animals, human healthy subjects and patients
- 8 November 2001
- Published by Elsevier in Life Sciences
- Vol. 69 (25-26) , 3103-3112
Mechanisms of action of retinoids in gastrointestinal mucosal protection in animals, human healthy subjects and patients
- Open Access
- 1 October 2001
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 16 (10) , 1093-1097
Four response stages of capsaicin‐sensitive primary afferent neurons to capsaicin and its analog: Gastric acid secretion, gastric mucosal damage and protection
Capsaicin is the active component of red hot peppers, which modifies specifically the capsaicin‐sensitive sensory afferent nerves. The action of capsaicin is an initial short‐lasting stimulation, which is followed by desensitization to capsaicin itself, and to other stimuli of afferent sensory nerves. Four response stages of capsaicin‐sensitive primary afferents exist to capsaicin, depending on the dose and duration of exposure to the drug. These are excitation, a sensory blocking effect, long‐term selective neurotoxic impairment, and irreversible cell destruction. The possible roles of four stages of capsaicin‐sensitive primary afferents can be evaluated in relation to gastric acid secretion, and to the details of the defensive side of gastric mucosa against different chemicals, physical agents, drugs and other pathological stress. Capsaicin inhibited the gastric acid secretion in pylorus‐ligated rats when it was given intragastrically at a dose of 0.4–1.8 μg/kg. Small doses of capsaicin (up to 800 μg, i.g.) produced a dose‐dependent inhibition (ID50 = 400 μg), and its inhibitory effect was exerted for 1 h in healthy human subjects. While a small dose (5 μg/kg) of capsaicin caused inhibition, a high dose (50–100 mg/kg) enhanced the gastric mucosal lesions productivity by causing hyperacidity in pylorus‐ligated animals. Capsaicin and its analog inhibited the development of different chemically induced gastric mucosal damage in various experimental models if they were given intragastric doses (μg/kg). The final effects of capsaicin depend on the dosage and timing. The different effects are excitation, a sensory‐blocking effect, long‐term selective neurotoxic impairment and irreversible cell destruction.
- 1 October 2001
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 16 (10) , 1093-1097
Open AccessFour response stages of capsaicin‐sensitive primary afferent neurons to capsaicin and its analog: Gastric acid secretion, gastric mucosal damage and protection
Capsaicin is the active component of red hot peppers, which modifies specifically the capsaicin‐sensitive sensory afferent nerves. The action of capsaicin is an initial short‐lasting stimulation, which is followed by desensitization to capsaicin itself, and to other stimuli of afferent sensory nerves. Four response stages of capsaicin‐sensitive primary afferents exist to capsaicin, depending on the dose and duration of exposure to the drug. These are excitation, a sensory blocking effect, long‐term selective neurotoxic impairment, and irreversible cell destruction. The possible roles of four stages of capsaicin‐sensitive primary afferents can be evaluated in relation to gastric acid secretion, and to the details of the defensive side of gastric mucosa against different chemicals, physical agents, drugs and other pathological stress. Capsaicin inhibited the gastric acid secretion in pylorus‐ligated rats when it was given intragastrically at a dose of 0.4–1.8 μg/kg. Small doses of capsaicin (up to 800 μg, i.g.) produced a dose‐dependent inhibition (ID50 = 400 μg), and its inhibitory effect was exerted for 1 h in healthy human subjects. While a small dose (5 μg/kg) of capsaicin caused inhibition, a high dose (50–100 mg/kg) enhanced the gastric mucosal lesions productivity by causing hyperacidity in pylorus‐ligated animals. Capsaicin and its analog inhibited the development of different chemically induced gastric mucosal damage in various experimental models if they were given intragastric doses (μg/kg). The final effects of capsaicin depend on the dosage and timing. The different effects are excitation, a sensory‐blocking effect, long‐term selective neurotoxic impairment and irreversible cell destruction.
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 29-33
Atropine-induced gastrointestinal cytoprotection dependences to the intact of vagal nerve against indomethacin-induced gastrointestinal mucosal and microvascular damage in rats
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 29-33
Atropine-induced gastrointestinal cytoprotection dependences to the intact of vagal nerve against indomethacin-induced gastrointestinal mucosal and microvascular damage in rats
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1) , 413-416
Multimodality treatment resulting in long-term survival in hepatocellular carcinoma
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1) , 413-416
Multimodality treatment resulting in long-term survival in hepatocellular carcinoma
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 489-494
Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract
- 1 January 2001
- Published by Elsevier in Journal of Physiology-Paris
- Vol. 95 (1-6) , 489-494
Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract